KRYS
HealthcareKrystal Biotech, Inc.
$244.71
$-2.20 (-0.89%)
Jan 5, 2026
Price History (1Y)
Analysis
Krystal Biotech, Inc. is a biotechnology company operating in the healthcare sector with a significant market presence, boasting a market capitalization of $7.10 billion and annual revenue of approximately $373 million. The company employs 275 individuals, indicating a substantial scale of operations. From a financial perspective, Krystal Biotech demonstrates impressive profitability margins, including a gross margin of 94.3%, operating margin of 42.3%, and profit margin of 53.3%. This is complemented by strong returns on equity (19.7%) and assets (8.9%), underscoring the company's ability to generate value from its operations. The balance sheet also shows a relatively low debt-to-equity ratio of 0.84, coupled with substantial cash reserves of $731 million. Krystal Biotech's valuation metrics suggest a premium positioning within its sector. The trailing P/E ratio stands at 37.02, while the forward P/E is slightly lower at 29.48. Notably, the company has achieved significant revenue and earnings growth over the past year, with rates of 16.6% and 192.3%, respectively. However, dividend information is not available for this company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $7.10B
- P/E Ratio
- 37.02
- 52-Week High
- $265.92
- 52-Week Low
- $122.80
- Avg Volume
- 292.51K
- Beta
- 0.46
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 275